AI-enabled virtual primary care
Doctronic
This profile covers Doctronic consumer consultation with optional clinical escalation. Patients choose the initial question and whether to seek further care. Commercial incentives require scrutiny, but this pass did not establish that users are forced toward paid care. Prescription-renewal deployments require separate assessment.
Published September 8, 2026 as an AI-assisted draft. The public report separates documented facts, agency judgments and unresolved questions.
Summary judgment · 75 out of 100 toward patient-directed
Doctronic anonymous AI consultation, distinct from identified member records, paid clinician visits, and prescription-renewal decisions. Consumer-directed entry into a vendor-operated care platform.
Potentially agency-expanding, with vendor-funnel and framing caveats
This profile covers Doctronic consumer consultation with optional clinical escalation. Patients choose the initial question and whether to seek further care. Commercial incentives require scrutiny, but this pass did not establish that users are forced toward paid care. Prescription-renewal deployments require separate assessment.
Patient agency
How this tool changes agency
Portable assessments and human review can support comparison and challenge. The source does not demonstrate that generated evidence is accurate or that a human reviewer evaluates independently.
Actual anonymous unlinkability, paid-escalation presentation, independent review mechanics, citation reliability, and renewal oversight.
Patient agency assessment
Who sets and changes the goal?
Patients can choose questions and an outside clinician. The evidence supports an offered paid pathway, not a demonstrated forced funnel. Member treatment and renewal workflows give the operator additional responsibilities and access.
What can the patient understand, question, or do?
Portable assessments and human review can support comparison and challenge. The source does not demonstrate that generated evidence is accurate or that a human reviewer evaluates independently.
Can the patient evaluate the conditions of use?
The policy offers unusually concrete rights, but headline clinical language and the AI disclaimer send different signals about reliance. Anonymous and identified use must not share one blanket privacy claim.
Text findings
Conditions of use
Published controls and their limits
The policy offers unusually concrete rights, but headline clinical language and the AI disclaimer send different signals about reliance. Anonymous and identified use must not share one blanket privacy claim.
What remains unknown?
Not tested or not established
Actual anonymous unlinkability, paid-escalation presentation, independent review mechanics, citation reliability, and renewal oversight.
Who evaluated this?
AI-assisted public-source draft
Vendor statements describe published conditions, not independently verified behavior. No clinical, security, accessibility, or legal validation is claimed. Earlier evidence remains dated in the report and history.
Sources checked
Source-specific findings and retrieval limitations are recorded in the full report.
Review provenance
Criteria
CAIHL-derived HugoScore framework and September 7 qualitative review priorities. Draft v1.2 numerical anchors remain unadopted.
Reviewer
AI-assisted public-source reassessment prepared in OpenAI Codex.
AI / model
OpenAI Codex / GPT-6
Human review
Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.
Review date
2026-09-08
Limitations
Actual anonymous unlinkability, paid-escalation presentation, independent review mechanics, citation reliability, and renewal oversight. No live product use, patient-data upload, account creation, code audit, clinical evaluation, or independent implementation validation.
Review method
Focused public-source reassessment using CAIHL: patient authority, critical capacity, and informed control. Existing evidence plus one focused primary-source pass and at most one targeted follow-up. No live product testing. Numerical scores remain provisional editorial placements, not a new calculation.
AI-assisted draft · Medium for published choices and rights (AI-assisted draft)